Safety of probiotics

Agro Food Industry Hi-Tech

Volumn 19, Issue 4, 2008, Pages 30-33

  Hibberd, Patricia L ^a,b   Davidson, Lisa E ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC RESISTANCE; BENEFICIAL EFFECTS; GASTROINTESTINAL TRACT; HEALTH BENEFITS; METABOLIC EFFECTS; OBSERVATIONAL STUDY; PROBIOTIC PRODUCTS; PRODUCT SAFETY;

FOOD TECHNOLOGY;

SAFETY ENGINEERING;

BACTERIA (MICROORGANISMS);

EID: 53849132051     PISSN: 17226996     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Food and Agriculture Organization of the United Nations and World Health Organization, "Health and Nutritional Properties of Probiotics", Food including Powder Milk with Live Lactic Acid Bacteria, ftp://ftp.fao.org/es/esn/ food/probio_report_en.pdf. 2001. Ref Type: Electronic Citation
2. N. Ishibashi, S. Yamazaki, "Probiotics and safety", Am J Clin Nutr., 73(2 Suppl), 465S-470S (2001).
3. K.M. Tuohy, H.M. Probert et al., "Using probiotics and prebiotics to improve gut health", Drug Discov Today, 8(15), pp. 692-700 (2003).
4. L. Edwards-Ingram, P. Gitsham et al., "Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiae", Appl Environ Microbiol., 73(8), pp. 2458-2467 (2007).
5. H. Amagase, "Current marketplace for probiotics: a Japanese perspective". Clin Infect Dis., 46 Suppl 2, S73-S75 (2008).
6. M. Saxelin, "Probiotic formulations and applications, the current probiotics market, and changes in the marketplace: a European perspective", Clin Infect Dis., 46 Suppl 2, S76-S79 (2008).
7. J.A. Vanderhoof, R. Young, "Probiotics in the United States", Clin Infect Dis., 46 Suppl 2, S67-S72 2008.
8. A. Mattia, R. Merker, "Regulation of probiotic substances as ingredients in foods: premarket approval or "generally recognized as safe" notification", Clin Infect Dis., 46 Suppl 2, S115-S118 (2008).
9. P.L. Hibberd, L. Davidson, "Probiotic foods and drugs: impact of US regulatory status on design of clinical trials", Clin Infect Dis., 46 Suppl 2, S137-S140 (2008).
10. F.A. Hoffman, J.T. Heimbach et al., "Executive summary: scientific and regulatory challenges of development of probiotics as foods and drugs", Clin Infect Dis., 46 Suppl 2, S53-S57 (2008).
11. A. Sutton, "Product development of probiotics as biological drugs", Clin Infect Dis., 46 Suppl 2, S128-S132 (2008).
12. A.C. Senok, AY. Ismaeel et al., "Probiotics: facts and myths", Clin Microbiol Infect., 11(12), pp. 958-966 (2005).
13. A.A. Salyers, A. Gupta et al., "Human intestinal bacteria as reservoirs for antibiotic resistance genes", Trends Microbiol., 12(9), pp. 412-416 (2004).
14. M. Saarela, G. Mogensen et al., "Probiotic bacteria: safety, functional and technological properties", J Biotechnol., 84(3), pp. 197-215 (2000).
15. A. Henriksson, T. Borody et al., "Probiotics under the regulatory microscope", Expert Opin Drug Saf, 4(6), pp. 1135-1143 (2005).
16. R.D. Berg, E. Wommack et al., "Immunosuppression and intestinal bacterial overgrowth synergistically promote bacterial translocation", Arch Surg., 123(11), pp. 1359-1364 (1988).
17. E.A. Deitch, K. Maejima et al., "Effect of oral antibiotics and bacterial overgrowth on the translocation of the Gl tract microflora in burned rats", J Trauma, 25(5), pp. 385-392 (1985).
18. B.S. Reddy, J. MacFie et al., "Commensal bacteria do translocate across the intestinal barrier in surgical patients", Clin Nutr., 26(2), pp. 208-215(2007).
19. J.S. Zhou, Q. Shu et al., "Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria", Food Chem Toxicol., 38(2-3), pp. 153-161 (2000).
20. J.S. Zhou, Q. Shu et al., "Safety assessment of potential probiotic lactic acid bacterial strains Lactobacillus rhamnosus HN001, Lb. acidophilus HN017, and Bifidobacterium lactis HN019 in BALB/c mice", Int J Food Microbiol., 56(1), pp. 87-96 (2000).
21. A.C. Ouwehand, S. Salminen et al., "Disease-dependent adhesion of lactic acid bacteria to the human intestinal mucosa", Clin Diagn Lab Immunol., 10(4), pp. 643-646 (2003).
22. A.V. Rodriguez, M.D. Baigori et al., "Phosphatidylinositol-specific phospholipase C activity in Lactobacillus rhamnosus with capacity to translocate", FEMS Microbiol Lett., 204(1), pp. 33-38 (2001).
23. S. Vesterlund, V. Vankerckhoven et al., "Safety assessment of Lactobacillus strains: presence of putative risk factors in faecal, blood and probiotic isolates", Int J Food Microbiol., 116(3), pp. 325-331 (2007).
24. M.G. Besselink, H.C. van Santvoort et al., "Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial", Lancet, 371(9613), pp. 651-659 (2008).
25. R.J. Boyle, RM. Robins-Browne et al., "Probiotic use in clinical practice: what are the risks?", Am J Clin Nutr., 83(6), pp. 1256-1264 (2006).
26. M. Rautio, H. Jousimies-Somer et al., "Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG", Clin Infect Dis., 28(5), pp. 1159-1160 (1999).
27. A.D. MacKay, M.B. Taylor et al., "Lactobacillus endocarditis caused by a probiotic organism", Clin Microbiol Infect., 5(5), pp. 290-292 (1999).
28. A.N. Kunz, J.M. Noel et al., "Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome", J Pediatr Gastroenterol Nutr., 38(4), pp. 457-458 (2004).
29. M.A. De Groote, D.N. Frank et al., "Lactobacillus rhamnosus GG bacteremia associated with probiotic use in a child with short gut syndrome", Pediatr Infect Dis J., 24(3), pp. 278-280 (2005).
30. M.H. Land, K. Rouster-Stevens et al., "Lactobacillus sepsis associated with probiotic therapy", Pediatrics, 115(1), pp. 178-181 (2005).